Search research articles
Contact Us
Filters
Showing results (31-40 of 52) with videos related to
Page
of 6
Sort By:
Biological Psychiatry
|
November 1, 1991
Lack of a bimodal distribution of ventricular size in schizophrenia: a Gaussian mixture analysis of 1056 cases and controls
D G Daniel, T E Goldberg, R D Gibbons, et al.
Archives of General Psychiatry
|
December 1, 1992
Ventricular enlargement in schizophrenia: is there really a gender effect?
J R Zigun, D G Daniel, J E Kleinman, et al.
Archives of General Psychiatry
|
December 1, 1992
Regional cerebral blood flow in monozygotic twins discordant and concordant for schizophrenia
K F Berman, E F Torrey, D G Daniel, et al.
The American Journal of Psychiatry
|
May 1, 1990
Left-handedness and ventricle size in schizophrenic patients
C Randolph, T E Goldberg, J Gold, et al.
Psychiatry Research
|
October 1, 1993
Regional cerebral blood flow during the Wisconsin Card Sorting Test in normal subjects studied by xenon-133 dynamic SPECT: comparison of absolute values, percent distribution values, and covariance analysis
S Marenco, R Coppola, D G Daniel, et al.
Schizophrenia Research
|
November 1, 1989
The relationship of occipital skull asymmetry to brain parenchymal measures in schizophrenia
D G Daniel, M S Myslobodsky, L J Ingraham, et al.
Schizophrenia Research
|
July 1, 1989
Shape analysis of the middle cranial fossa of schizophrenic patients. A computerized tomographic study
M F Casanova, D G Daniel, T E Goldberg, et al.
The American Journal of Psychiatry
|
January 1, 1991
Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia
T E Goldberg, L B Bigelow, D R Weinberger, et al.
Psychopharmacology
|
June 13, 2001
Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial
D G Daniel, S G Potkin, K R Reeves, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
April 8, 1999
Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group
D G Daniel, D L Zimbroff, S G Potkin, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 52) with videos related to
Sort By:
Page
of 6
Biological Psychiatry
|
November 1, 1991
Lack of a bimodal distribution of ventricular size in schizophrenia: a Gaussian mixture analysis of 1056 cases and controls
D G Daniel, T E Goldberg, R D Gibbons, et al.
Archives of General Psychiatry
|
December 1, 1992
Ventricular enlargement in schizophrenia: is there really a gender effect?
J R Zigun, D G Daniel, J E Kleinman, et al.
Archives of General Psychiatry
|
December 1, 1992
Regional cerebral blood flow in monozygotic twins discordant and concordant for schizophrenia
K F Berman, E F Torrey, D G Daniel, et al.
The American Journal of Psychiatry
|
May 1, 1990
Left-handedness and ventricle size in schizophrenic patients
C Randolph, T E Goldberg, J Gold, et al.
Psychiatry Research
|
October 1, 1993
Regional cerebral blood flow during the Wisconsin Card Sorting Test in normal subjects studied by xenon-133 dynamic SPECT: comparison of absolute values, percent distribution values, and covariance analysis
S Marenco, R Coppola, D G Daniel, et al.
Schizophrenia Research
|
November 1, 1989
The relationship of occipital skull asymmetry to brain parenchymal measures in schizophrenia
D G Daniel, M S Myslobodsky, L J Ingraham, et al.
Schizophrenia Research
|
July 1, 1989
Shape analysis of the middle cranial fossa of schizophrenic patients. A computerized tomographic study
M F Casanova, D G Daniel, T E Goldberg, et al.
The American Journal of Psychiatry
|
January 1, 1991
Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia
T E Goldberg, L B Bigelow, D R Weinberger, et al.
Psychopharmacology
|
June 13, 2001
Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial
D G Daniel, S G Potkin, K R Reeves, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
April 8, 1999
Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group
D G Daniel, D L Zimbroff, S G Potkin, et al.
Page
of 6